The company is issuing a €2m green bond and is separating the conventional and renewable activities. The latter was already announced early…

During the H1 21 operating results release, the developments in the battery business again stole the limelight. With tangible progress in battery…

DEE Tech, a SPAC that counts with IDI as sponsor and investor, has entered into exclusive talks with Colis Privé, one of…

Cementir Holding has published a good set of 9M 21 results. All regions saw a good rally in demand. Denmark was the…

Chargeurs released a solid set of results in Q3, with Protective Films continuing to perform strongly and Fashion Technologies showing signs that…

Ikonisys reported soft H1 21 results. However, the firm has recently hired a new sales director in the US, who should help…

Cementir Holding has set an aggressive emission target for 2030, aiming for one of the lowest emission rates in the sector, despite…

The net loss came in below expectations, most likely due to temporary unemployment measures phasing out but the outlook is positive, supported…

Delta Drone’s half year earnings suffered from a combination of delayed business (lasting Covid impacts on orders) and delayed booking of acquisitions…

AlphaValue is supportive of the French regulator (AMF) efforts to ensure a level field when it comes to sponsored research. Through an…

Just a few months after being acquired by IDI, Groupe Talis has made its first acquisition to expand its reach in the…

Drone Volt has announced strong growth in Q3 due to the positive execution of its contracts with Aquiline Drones. Its ramp-up of…

During the H1 21 operating results release, the developments in the battery business again stole the limelight. With tangible progress in battery…

SFPI released impressive H1 earnings. H2 looks promising too. Ideal operating conditions may not survive into 2022. SFPI had kept market expectations…

H1 was a half year full of exciting news for Drone Volt. Its partnership with Aquiline Drones strengthened significantly through a disposal…

The H1 21 results were in line with expectationsThe group continues its efforts on Midazolam, Hydrocortisone and AdrenalineThe bioequivalence study for Midazolam…

We initiate coverage of IDI with a “Buy” recommendation. IDI strikes us as a private equity firm more aligned to the interests…

The company reported an encouraging first half, driven by the strong performance of Protective Films and Healthcare Solutions, though all divisions contributed…

We had initiated coverage of Chargeurs as a holding company then battling on to pay back its debt,. However, the strategy pursued…

Strong set of H1 FY21 results thanks to both easy comps linked to the pandemic and, especially, the continuing evolution of the…

We have updated our model following the acquisition of 8.2 France. EPS 2021 and 2022 are up on the consolidation of 8.2…

Swissquote released this morning its numbers for H1 21. These are in line with Swissquote’s profit positive warning announced in mid-June. Revenues…

The acquisition of 8.2 France is complete and Dolfines has signed a financing agreement with an investment company to implement its strategic…

Cementir Holding has published its H1 21 results. All regions saw a strong rally in volume sales due to a weak comparison…

Diagnostic firm Ikonisys is set to enter a major product launch cycle – its recently-introduced ‘fully-automated’ Ikoniscope20 platform comes with an industry…

The company released a positive update which triggered a 60% spike in the stock price. While there are various elements in the…

Drone Volt has published solid H1 results, driven by its major contracts with Aquiline Drones and Central Europe starting to generate revenues….

Drone Volt has finalised this highly anticipated sale to its American partner Aquiline Drones at a valuation of €15m, which represents an…

The Barda has launched its call for tender on Midazolam autoinjector. Crossject is in a good position to compete. This could boost…

Zeneo Hydrocortisone to be licensed in the US and Canada.The news confirms the pharmaceutical firms’ interest in Crossject’s product.The remuneration of the…